2
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
211
Triple Negative Breast Neoplasms
32
Stomach Neoplasms
32
Inflammatory Breast Neoplasms
21
Esophageal Neoplasms
16
Carcinoma, Hepatocellular
15
Lymphoma, Large B-Cell, Diffuse
9
Sarcoma
8
Neoplasms
8
Non-Muscle Invasive Bladder Neoplasms
6
Urinary Bladder Neoplasms
5
Pancreatic Neoplasms
5
Liver Neoplasms
5
Breast Neoplasms, Male
5
Adenocarcinoma Of Esophagus
5
Ovarian Neoplasms
4
Lymphoma
4
Testicular Neoplasms
3
Primary Breast Cancer
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pathologic Complete Response
3
Hemangiosarcoma
3
Gallbladder Neoplasms
3
Carcinoma, Ductal, Breast
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Recurrence
2
Prostatic Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neoplastic Cells, Circulating
2
Interventions
Gemcitabine
95
Cisplatin
72
Capecitabine
39
Oxaliplatin
38
durvalumab
29
Fluorouracil
27
pembrolizumab
26
Leucovorin
23
S 1 (combination)
19
Nivolumab
14
Irinotecan
14
lenvatinib
13
Bevacizumab
13
tremelimumab
10
130-nm albumin-bound paclitaxel
9
apatinib
8
Trastuzumab
7
Injections
7
Immune Checkpoint Inhibitors
7
Docetaxel
7
Albumin-Bound Paclitaxel
7
Paclitaxel
6
Drug Therapy
6
titanium silicide
5
surufatinib
5
irinotecan sucrosofate
5
gemcitabine-oxaliplatin regimen
5
envafolimab
5
camrelizumab
5
atezolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Epirubicin
×
Clear all
NCT03668418
2018-09-12
xenoZ
University of Pisa
Unknown
120 enrolled